ArticleTranslational cancer research2026
TRIM32 drives head and neck squamous cell carcinoma progression via TP53 suppression and lysosomal/autophagy dysregulation.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The TRIM32 has been implicated in tumorigenesis across various cancers; however, its functional significance in head and neck squamous cell carcinoma (HNSCC) requires systematic investigation. This study sought to explore the expression and biological function of TRIM32 in HNSCC tissues to identify new targets or biomarkers for HNSCC diagnosis and treatment. Methods: HNSCC samples were extracted for TRIM32 expression profiling, with subsequent integration of clinical samples for validation. Gene Set Enrichment Analysis (GSEA) was performed using the c2.cp.kegg.v7.4.symbols.gmt gene set. Immune cell infiltration was evaluated using the ESTIMATE algorithm. Following TRIM32 knockdown via small interfering RNA (siRNA) in HNSCC cell lines (HSC-3, FADU), proliferation and invasion capacities were assessed using Cell Counting Kit-8 (CCK-8) and Transwell assays, respectively. Western blotting was conducted to analyse protein expression within the TRIM32-p53-LAMP1/2-LC3B pathway. Results: Integrated bioinformatics analysis and clinical sample validation revealed significantly elevated TRIM32 expression in HNSCC, correlating with poor patient prognosis. GSEA demonstrated significant enrichment of autophagy and p53 signalling pathways within the TRIM32 high-expression group. Conclusions: TRIM32 expression is significantly elevated in HNSCC, indicating its potential as an adverse prognostic marker. Experimental evidence demonstrates that TRIM32 facilitates cellular proliferation and migration, significantly influences lysosomal function and autophagy processes within HNSCC cells, and is verified to negatively regulate tumour protein 53 (TP53). These mechanisms contribute to the aggressive behaviour of HNSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.